Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

Study Overview

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

Study Description

A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors

  • Identifier: NCT03364400
  • Protocol Number: 18-609
  • Principal Investigator: Andrea Bullock

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000